Literature DB >> 27938734

[Principles for the evaluation of telemedicine applications: Results of a systematic review and consensus process].

Katrin Arnold1, Madlen Scheibe2, Olaf Müller3, Jochen Schmitt4.   

Abstract

BACKGROUND: The limited number of telemedicine applications being transferred to standard medical care in Germany may to some extent be explained by deficits in the current evaluation practice. Effectiveness and cost effectiveness can only be demonstrated to decision makers and potential users with methodologically sound and fully published evaluations. There is a lack of well-founded and mandatory standards for adequate, comparable evaluations of telemedicine applications.
METHODS: As part of the project CCS Telehealth Eastern Saxony (CCS THOS), a systematic review on evaluation concepts for telemedicine applications (search period until September 2014, databases Medline, Embase, HTA-Database, DARE, NHS EED) as well as an additional selective literature search were conducted. Suggestions for evaluation fundamentals were derived from the results. These suggestions were subjected to a formal consensus process (nominal group process) with relevant stakeholder groups (healthcare payers, healthcare providers, health policy representatives, researchers).
RESULTS: 19 papers were included in the systematic review. In accordance with the predefined inclusion criteria, each presented an evaluation concept for telemedicine applications that was based upon a systematic review and/or a consensus process. Via a formal consensus process, the suggestions for evaluation principles derived from the review and the selective literature search (23 papers) resulted in ten agreed evaluation principles. Eight of them were unanimously agreed upon, two were arrived at with one abstention each. The principles enclose criteria for the planning, conduct and reporting of telemedicine evaluations. Adherence to them is obligatory for users of the telemedical infrastructure provided by CCS THOS. Furthermore, right from the beginning the intention was very much for these principles to be seized upon by other projects and initiatives.
CONCLUSIONS: The agreed evaluation principles for telemedicine applications are the first in Germany to be based both upon evidence and consensus. Due to the methodology of development, they have a strong scientific and health policy legitimation. Therefore, and because of their general applicability, adherence to these principles beyond the context of the telemedicine platform developed within CCS THOS is recommended, namely throughout the German telemedicine scene.
Copyright © 2016. Published by Elsevier GmbH.

Entities:  

Keywords:  Evaluation; Konsens; Qualität; Review; Telemedizin; consensus; evaluation; quality; review; telemedicine

Mesh:

Year:  2016        PMID: 27938734     DOI: 10.1016/j.zefq.2016.04.011

Source DB:  PubMed          Journal:  Z Evid Fortbild Qual Gesundhwes        ISSN: 1865-9217


  4 in total

1.  [Acceptance of Care Offers for exclusive Remote Treatment Illustrated by the Telemedical Model Project "docdirekt" with a Mixed-Methods Design].

Authors:  Michail von Solodkoff; Christoph Strumann; Jost Steinhäuser
Journal:  Gesundheitswesen       Date:  2020-07-02

2.  Video-based smartphone app ('VIDEA bewegt') for physical activity support in German adults: a single-armed observational study.

Authors:  Tillmann Fischer; Paul Stumpf; Peter E H Schwarz; Patrick Timpel
Journal:  BMJ Open       Date:  2022-01-25       Impact factor: 2.692

3.  Determinants of the Implementation of Telemedicine in the German Navy-A Mixed Methods Study.

Authors:  Ensign Daniel Valentin Hötker; Markus Matthias Ring; Jost Steinhäuser
Journal:  Mil Med       Date:  2022-05-03       Impact factor: 1.563

Review 4.  Use of Patient-Reported Outcome Measures and Patient-Reported Experience Measures Within Evaluation Studies of Telemedicine Applications: Systematic Review.

Authors:  Andreas Knapp; Lorenz Harst; Stefan Hager; Jochen Schmitt; Madlen Scheibe
Journal:  J Med Internet Res       Date:  2021-11-17       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.